ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Hepatitis B Treatment Oral Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-13N17276
Home | Market Reports | Health| Pharmacy
Global Chronic Hepatitis B Treatment Oral Drugs Market Research Report 2024
BUY CHAPTERS

Global Chronic Hepatitis B Treatment Oral Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-13N17276
Report
November 2025
Pages:142
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu Pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Johnson & Johnson

Chronic Hepatitis B Treatment Oral Drugs Market

The global Chronic Hepatitis B Treatment Oral Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Chronic Hepatitis B Treatment Oral Drugs leading manufacturers including GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with GSK leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Chronic Hepatitis B Treatment Oral Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Chronic Hepatitis B Treatment Oral Drugs Market Report

Report Metric Details
Report Name Chronic Hepatitis B Treatment Oral Drugs Market
Segment by Type
  • Entecavir
  • Tenofovir
  • Lamivudine
  • Adefovir
  • Telbivudine
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, Qilu pharmaceutical, Fujian Cosunter Pharma, Xiamen Amoytop Biotech, YaoPharma, Kelun Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Chronic Hepatitis B Treatment Oral Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Chronic Hepatitis B Treatment Oral Drugs Market report?

Ans: The main players in the Chronic Hepatitis B Treatment Oral Drugs Market are GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, Qilu pharmaceutical, Fujian Cosunter Pharma, Xiamen Amoytop Biotech, YaoPharma, Kelun Pharmaceutical

What are the Application segmentation covered in the Chronic Hepatitis B Treatment Oral Drugs Market report?

Ans: The Applications covered in the Chronic Hepatitis B Treatment Oral Drugs Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Chronic Hepatitis B Treatment Oral Drugs Market report?

Ans: The Types covered in the Chronic Hepatitis B Treatment Oral Drugs Market report are Entecavir, Tenofovir, Lamivudine, Adefovir, Telbivudine, Others

1 Study Coverage
1.1 Introduction to Chronic Hepatitis B Treatment Oral Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 Market Segmentation by Application
1.3.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Chronic Hepatitis B Treatment Oral Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Chronic Hepatitis B Treatment Oral Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Chronic Hepatitis B Treatment Oral Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Entecavir Market Size by Players
3.3.2 Tenofovir Market Size by Players
3.3.3 Lamivudine Market Size by Players
3.3.4 Adefovir Market Size by Players
3.3.5 Telbivudine Market Size by Players
3.3.6 Others Market Size by Players
3.4 Global Chronic Hepatitis B Treatment Oral Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Chronic Hepatitis B Treatment Oral Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Type (2020-2031)
6.4 North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Type (2020-2031)
7.4 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Chronic Hepatitis B Treatment Oral Drugs Market Size by Type (2020-2031)
9.4 Central and South America Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.1.4 GSK Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.1.5 GSK Chronic Hepatitis B Treatment Oral Drugs Revenue by Product in 2024
11.1.6 GSK Chronic Hepatitis B Treatment Oral Drugs Revenue by Application in 2024
11.1.7 GSK Chronic Hepatitis B Treatment Oral Drugs Revenue by Geographic Area in 2024
11.1.8 GSK Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
11.1.9 GSK Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Corporation Information
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.2.4 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.2.5 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Revenue by Product in 2024
11.2.6 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Revenue by Application in 2024
11.2.7 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Revenue by Geographic Area in 2024
11.2.8 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
11.2.9 Bristol Myers Squibb Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.3.4 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Revenue by Product in 2024
11.3.6 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Revenue by Application in 2024
11.3.7 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Revenue by Geographic Area in 2024
11.3.8 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.4.4 Novartis Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Chronic Hepatitis B Treatment Oral Drugs Revenue by Product in 2024
11.4.6 Novartis Chronic Hepatitis B Treatment Oral Drugs Revenue by Application in 2024
11.4.7 Novartis Chronic Hepatitis B Treatment Oral Drugs Revenue by Geographic Area in 2024
11.4.8 Novartis Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.5.4 Roche Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Roche Chronic Hepatitis B Treatment Oral Drugs Revenue by Product in 2024
11.5.6 Roche Chronic Hepatitis B Treatment Oral Drugs Revenue by Application in 2024
11.5.7 Roche Chronic Hepatitis B Treatment Oral Drugs Revenue by Geographic Area in 2024
11.5.8 Roche Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
11.5.9 Roche Recent Developments
11.6 Merck
11.6.1 Merck Corporation Information
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.6.4 Merck Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.6.5 Merck Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Corporation Information
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.7.4 Johnson & Johnson Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Johnson & Johnson Recent Developments
11.8 Dawnrays Pharmaceutical
11.8.1 Dawnrays Pharmaceutical Corporation Information
11.8.2 Dawnrays Pharmaceutical Business Overview
11.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.8.4 Dawnrays Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.8.5 Dawnrays Pharmaceutical Recent Developments
11.9 Hansoh Pharmaceutical
11.9.1 Hansoh Pharmaceutical Corporation Information
11.9.2 Hansoh Pharmaceutical Business Overview
11.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.9.4 Hansoh Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.9.5 Hansoh Pharmaceutical Recent Developments
11.10 Chia Tai-Tianqing Pharmaceutical
11.10.1 Chia Tai-Tianqing Pharmaceutical Corporation Information
11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview
11.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.10.4 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Qilu pharmaceutical
11.11.1 Qilu pharmaceutical Corporation Information
11.11.2 Qilu pharmaceutical Business Overview
11.11.3 Qilu pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.11.4 Qilu pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.11.5 Qilu pharmaceutical Recent Developments
11.12 Fujian Cosunter Pharma
11.12.1 Fujian Cosunter Pharma Corporation Information
11.12.2 Fujian Cosunter Pharma Business Overview
11.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.12.4 Fujian Cosunter Pharma Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.12.5 Fujian Cosunter Pharma Recent Developments
11.13 Xiamen Amoytop Biotech
11.13.1 Xiamen Amoytop Biotech Corporation Information
11.13.2 Xiamen Amoytop Biotech Business Overview
11.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.13.4 Xiamen Amoytop Biotech Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.13.5 Xiamen Amoytop Biotech Recent Developments
11.14 YaoPharma
11.14.1 YaoPharma Corporation Information
11.14.2 YaoPharma Business Overview
11.14.3 YaoPharma Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.14.4 YaoPharma Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.14.5 YaoPharma Recent Developments
11.15 Kelun Pharmaceutical
11.15.1 Kelun Pharmaceutical Corporation Information
11.15.2 Kelun Pharmaceutical Business Overview
11.15.3 Kelun Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product Features and Attributes
11.15.4 Kelun Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Revenue and Gross Margin (2020-2025)
11.15.5 Kelun Pharmaceutical Recent Developments
12 Chronic Hepatitis B Treatment Oral DrugsIndustry Chain Analysis
12.1 Chronic Hepatitis B Treatment Oral Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Chronic Hepatitis B Treatment Oral Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Chronic Hepatitis B Treatment Oral Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu Pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Johnson & Johnson
List of Tables
 Table 1. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Chronic Hepatitis B Treatment Oral Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Hepatitis B Treatment Oral Drugs as of 2024)
 Table 11. Global Chronic Hepatitis B Treatment Oral Drugs Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Chronic Hepatitis B Treatment Oral Drugs Companies Headquarters
 Table 13. Global Chronic Hepatitis B Treatment Oral Drugs Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Chronic Hepatitis B Treatment Oral Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Chronic Hepatitis B Treatment Oral Drugs Growth Accelerators and Market Barriers
 Table 25. North America Chronic Hepatitis B Treatment Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Chronic Hepatitis B Treatment Oral Drugs Growth Accelerators and Market Barriers
 Table 27. Europe Chronic Hepatitis B Treatment Oral Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Chronic Hepatitis B Treatment Oral Drugs Investment Opportunities and Key Challenges
 Table 31. Central and South America Chronic Hepatitis B Treatment Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Chronic Hepatitis B Treatment Oral Drugs Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Chronic Hepatitis B Treatment Oral Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. GSK Corporation Information
 Table 35. GSK Description and Major Businesses
 Table 36. GSK Product Features and Attributes
 Table 37. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. GSK Revenue Proportion by Product in 2024
 Table 39. GSK Revenue Proportion by Application in 2024
 Table 40. GSK Revenue Proportion by Geographic Area in 2024
 Table 41. GSK Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
 Table 42. GSK Recent Developments
 Table 43. Bristol Myers Squibb Corporation Information
 Table 44. Bristol Myers Squibb Description and Major Businesses
 Table 45. Bristol Myers Squibb Product Features and Attributes
 Table 46. Bristol Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Bristol Myers Squibb Revenue Proportion by Product in 2024
 Table 48. Bristol Myers Squibb Revenue Proportion by Application in 2024
 Table 49. Bristol Myers Squibb Revenue Proportion by Geographic Area in 2024
 Table 50. Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
 Table 51. Bristol Myers Squibb Recent Developments
 Table 52. Gilead Sciences Corporation Information
 Table 53. Gilead Sciences Description and Major Businesses
 Table 54. Gilead Sciences Product Features and Attributes
 Table 55. Gilead Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Gilead Sciences Revenue Proportion by Product in 2024
 Table 57. Gilead Sciences Revenue Proportion by Application in 2024
 Table 58. Gilead Sciences Revenue Proportion by Geographic Area in 2024
 Table 59. Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
 Table 60. Gilead Sciences Recent Developments
 Table 61. Novartis Corporation Information
 Table 62. Novartis Description and Major Businesses
 Table 63. Novartis Product Features and Attributes
 Table 64. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Novartis Revenue Proportion by Product in 2024
 Table 66. Novartis Revenue Proportion by Application in 2024
 Table 67. Novartis Revenue Proportion by Geographic Area in 2024
 Table 68. Novartis Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
 Table 69. Novartis Recent Developments
 Table 70. Roche Corporation Information
 Table 71. Roche Description and Major Businesses
 Table 72. Roche Product Features and Attributes
 Table 73. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Roche Revenue Proportion by Product in 2024
 Table 75. Roche Revenue Proportion by Application in 2024
 Table 76. Roche Revenue Proportion by Geographic Area in 2024
 Table 77. Roche Chronic Hepatitis B Treatment Oral Drugs SWOT Analysis
 Table 78. Roche Recent Developments
 Table 79. Merck Corporation Information
 Table 80. Merck Description and Major Businesses
 Table 81. Merck Product Features and Attributes
 Table 82. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Merck Recent Developments
 Table 84. Johnson & Johnson Corporation Information
 Table 85. Johnson & Johnson Description and Major Businesses
 Table 86. Johnson & Johnson Product Features and Attributes
 Table 87. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Johnson & Johnson Recent Developments
 Table 89. Dawnrays Pharmaceutical Corporation Information
 Table 90. Dawnrays Pharmaceutical Description and Major Businesses
 Table 91. Dawnrays Pharmaceutical Product Features and Attributes
 Table 92. Dawnrays Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Dawnrays Pharmaceutical Recent Developments
 Table 94. Hansoh Pharmaceutical Corporation Information
 Table 95. Hansoh Pharmaceutical Description and Major Businesses
 Table 96. Hansoh Pharmaceutical Product Features and Attributes
 Table 97. Hansoh Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Hansoh Pharmaceutical Recent Developments
 Table 99. Chia Tai-Tianqing Pharmaceutical Corporation Information
 Table 100. Chia Tai-Tianqing Pharmaceutical Description and Major Businesses
 Table 101. Chia Tai-Tianqing Pharmaceutical Product Features and Attributes
 Table 102. Chia Tai-Tianqing Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Chia Tai-Tianqing Pharmaceutical Recent Developments
 Table 104. Qilu pharmaceutical Corporation Information
 Table 105. Qilu pharmaceutical Description and Major Businesses
 Table 106. Qilu pharmaceutical Product Features and Attributes
 Table 107. Qilu pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Qilu pharmaceutical Recent Developments
 Table 109. Fujian Cosunter Pharma Corporation Information
 Table 110. Fujian Cosunter Pharma Description and Major Businesses
 Table 111. Fujian Cosunter Pharma Product Features and Attributes
 Table 112. Fujian Cosunter Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Fujian Cosunter Pharma Recent Developments
 Table 114. Xiamen Amoytop Biotech Corporation Information
 Table 115. Xiamen Amoytop Biotech Description and Major Businesses
 Table 116. Xiamen Amoytop Biotech Product Features and Attributes
 Table 117. Xiamen Amoytop Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Xiamen Amoytop Biotech Recent Developments
 Table 119. YaoPharma Corporation Information
 Table 120. YaoPharma Description and Major Businesses
 Table 121. YaoPharma Product Features and Attributes
 Table 122. YaoPharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. YaoPharma Recent Developments
 Table 124. Kelun Pharmaceutical Corporation Information
 Table 125. Kelun Pharmaceutical Description and Major Businesses
 Table 126. Kelun Pharmaceutical Product Features and Attributes
 Table 127. Kelun Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Kelun Pharmaceutical Recent Developments
 Table 129. Raw Materials Key Suppliers
 Table 130. Distributors List
 Table 131. Market Trends and Market Evolution
 Table 132. Market Drivers and Opportunities
 Table 133. Market Challenges, Risks, and Restraints
 Table 134. Research Programs/Design for This Report
 Table 135. Key Data Information from Secondary Sources
 Table 136. Key Data Information from Primary Sources


List of Figures
 Figure 1. Chronic Hepatitis B Treatment Oral Drugs Product Picture
 Figure 2. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Entecavir Product Picture
 Figure 4. Tenofovir Product Picture
 Figure 5. Lamivudine Product Picture
 Figure 6. Adefovir Product Picture
 Figure 7. Telbivudine Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Others
 Figure 13. Chronic Hepatitis B Treatment Oral Drugs Report Years Considered
 Figure 14. Global Chronic Hepatitis B Treatment Oral Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 16. Global Chronic Hepatitis B Treatment Oral Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 17. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Region (2020-2031)
 Figure 18. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. Entecavir Revenue Market Share by Player in 2024
 Figure 21. Tenofovir Revenue Market Share by Player in 2024
 Figure 22. Lamivudine Revenue Market Share by Player in 2024
 Figure 23. Adefovir Revenue Market Share by Player in 2024
 Figure 24. Telbivudine Revenue Market Share by Player in 2024
 Figure 25. Others Revenue Market Share by Player in 2024
 Figure 26. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Type (2020-2031)
 Figure 27. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Application (2020-2031)
 Figure 28. North America Chronic Hepatitis B Treatment Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. North America Top 5 Players Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) in 2024
 Figure 30. North America Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Type (2020 - 2031)
 Figure 31. North America Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 32. US Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 33. Canada Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 34. Mexico Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 35. Europe Chronic Hepatitis B Treatment Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 36. Europe Top 5 Players Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) in 2024
 Figure 37. Europe Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 38. Europe Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 39. Germany Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 40. France Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 41. U.K. Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 42. Italy Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 43. Russia Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 44. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 45. Asia-Pacific Top 8 Players Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) in 2024
 Figure 46. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 47. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 48. Indonesia Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 49. Japan Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 50. South Korea Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 51. Australia Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 52. India Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 53. Indonesia Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 54. Vietnam Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 55. Malaysia Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 56. Philippines Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 57. Singapore Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2031) & (US$ Million)
 Figure 58. Central and South America Chronic Hepatitis B Treatment Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 59. Central and South America Top 5 Players Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) in 2024
 Figure 60. Central and South America Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 61. Central and South America Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 62. Brazil Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2025) & (US$ Million)
 Figure 63. Argentina Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2025) & (US$ Million)
 Figure 64. Middle East and Africa Chronic Hepatitis B Treatment Oral Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 65. Middle East and Africa Top 5 Players Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) in 2024
 Figure 66. South America Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 67. Middle East and Africa Chronic Hepatitis B Treatment Oral Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 68. GCC Countries Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2025) & (US$ Million)
 Figure 69. Israel Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2025) & (US$ Million)
 Figure 70. Egypt Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2025) & (US$ Million)
 Figure 71. South Africa Chronic Hepatitis B Treatment Oral Drugs Revenue (2020-2025) & (US$ Million)
 Figure 72. Chronic Hepatitis B Treatment Oral Drugs Industry Chain Mapping
 Figure 73. Channels of Distribution (Direct Vs Distribution)
 Figure 74. Bottom-up and Top-down Approaches for This Report
 Figure 75. Data Triangulation
 Figure 76. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Chronic Hepatitis B Oral Drugs Market Research Report 2024
Global Chronic Hepatitis C Treatment Oral Medicine Market Research Report 2024
Global Chronic Hepatitis C Treatment Drugs Market Research Report 2024
Hepatitis B Virus Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adult Chronic Hepatitis B Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti HBV Drugs Market Research Report 2025
Global Oral Anti HBV Drugs Market Research Report 2024
Global Oral Antiviral Medicine Market Research Report 2025
Global Hepatitis B Diagnostic Tests Market Research Report 2024
Anti Hepatitis Virus Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chronic Hepatitis B Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hepatitis B Treatment Market Insights Forecast to 2030
Hepatitis B Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hepatic Antiviral Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oral Antiviral Medicines for COVID 19 Market Research Report 2024
Global Oral Azvudine Tablets Market Research Report 2024
Global Hepatitis B Human Immunoglobulin Market Research Report 2024
Hepatitis B Therapeutic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chronic Liver Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Liver Cancer Treatment Drug Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions